JP2024515459A5 - - Google Patents
Info
- Publication number
- JP2024515459A5 JP2024515459A5 JP2023558203A JP2023558203A JP2024515459A5 JP 2024515459 A5 JP2024515459 A5 JP 2024515459A5 JP 2023558203 A JP2023558203 A JP 2023558203A JP 2023558203 A JP2023558203 A JP 2023558203A JP 2024515459 A5 JP2024515459 A5 JP 2024515459A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- approximately
- composition according
- identity
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163180646P | 2021-04-27 | 2021-04-27 | |
| US63/180,646 | 2021-04-27 | ||
| PCT/US2022/071937 WO2022232790A1 (en) | 2021-04-27 | 2022-04-26 | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515459A JP2024515459A (ja) | 2024-04-10 |
| JP2024515459A5 true JP2024515459A5 (https=) | 2025-04-28 |
Family
ID=81984711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558203A Pending JP2024515459A (ja) | 2021-04-27 | 2022-04-26 | アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240197915A1 (https=) |
| EP (1) | EP4329721A1 (https=) |
| JP (1) | JP2024515459A (https=) |
| KR (1) | KR20240005764A (https=) |
| CN (1) | CN117222400A (https=) |
| BR (1) | BR112023019056A2 (https=) |
| CA (1) | CA3215855A1 (https=) |
| MX (1) | MX2023012410A (https=) |
| WO (1) | WO2022232790A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| KR20260005446A (ko) | 2024-07-03 | 2026-01-12 | 김성훈 | 김치 제조 장치 |
| KR20260006393A (ko) | 2024-07-04 | 2026-01-13 | 김성훈 | 가정용 김치 제조 장치 |
| WO2026019885A1 (en) * | 2024-07-16 | 2026-01-22 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| AU2017257169B2 (en) * | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CA3147843A1 (en) * | 2019-09-11 | 2021-03-18 | Mehdi Gasmi | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| WO2021050094A1 (en) | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| HRP20260137T1 (hr) | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
-
2022
- 2022-04-26 BR BR112023019056A patent/BR112023019056A2/pt unknown
- 2022-04-26 MX MX2023012410A patent/MX2023012410A/es unknown
- 2022-04-26 KR KR1020237040171A patent/KR20240005764A/ko active Pending
- 2022-04-26 CN CN202280030462.0A patent/CN117222400A/zh active Pending
- 2022-04-26 WO PCT/US2022/071937 patent/WO2022232790A1/en not_active Ceased
- 2022-04-26 US US18/554,965 patent/US20240197915A1/en active Pending
- 2022-04-26 JP JP2023558203A patent/JP2024515459A/ja active Pending
- 2022-04-26 CA CA3215855A patent/CA3215855A1/en active Pending
- 2022-04-26 EP EP22729004.6A patent/EP4329721A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515459A5 (https=) | ||
| JP2022547541A5 (https=) | ||
| JP2025506383A5 (https=) | ||
| FI4027983T3 (fi) | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla | |
| US20240327481A1 (en) | Growth differentiation factor 15 fusion proteins | |
| CN100389820C (zh) | 含肉毒神经毒素的治疗剂 | |
| JP2024016207A5 (https=) | ||
| JP2021503914A5 (https=) | ||
| US10098905B2 (en) | Immunomodulating gene therapy | |
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2022511776A5 (https=) | ||
| JP2020537637A5 (https=) | ||
| JP2020526514A5 (https=) | ||
| JP2022522776A5 (https=) | ||
| JP2025506681A5 (https=) | ||
| JP2021511030A5 (https=) | ||
| JP2024517143A5 (https=) | ||
| JP2024517710A5 (https=) | ||
| JP2022512589A5 (https=) | ||
| JP2023545229A5 (https=) | ||
| MX2024010002A (es) | Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante | |
| JP2024511024A (ja) | ２１－ヒドロキシラーゼ欠損症の遺伝子治療 | |
| CN101213305A (zh) | 转基因在哺乳动物中枢神经系统中的可调控型表达 | |
| EP4149622A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| JP2025509568A5 (https=) |